港股異動丨信達生物(1801.HK)漲4.63% 攜手禮來公佈ORIENT-12研究結果
格隆匯9月21日丨信達生物(1801.HK)漲4.63%,報65.55港元,總市值917.5億港元。信達生物和禮來製藥共同宣佈,在2020年歐洲腫瘤內科學會(ESMO)線上年會以口頭報告形式公佈ORIENT-12研究結果。信達生物醫學科學與戰略腫瘤部副總裁周輝博士表示:“目前達伯舒®(信迪利單抗注射液)是唯一列入國家醫保目錄的抗PD-1單克隆抗體藥物。ORIENT-12結果令人鼓舞,國家藥品監督管理局已正式受理信迪利單抗該新適應症申請。統計數據顯示,9月16日,信達生物被南向資金淨買入1.95億元;9月17日再度淨買入1.55億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.